|View printer-friendly version|
|St. Jude Medical Announces Next-Generation PressureWire for FFR Measurement|
The new PressureWire with Agile Tip provides improved handling performance during FFR measurement procedures
The PressureWire with Agile Tip was designed to replicate the performance of standard percutaneous coronary intervention (PCI) guidewires and delivers exceptional handling even in the most challenging anatomies. Available in both of the company’s Aeris (wireless) and Certus PressureWire models, this eighth-generation guidewire also can deliver interventional tools more easily, for faster and more cost-effective PCI.
Another new feature in the next-generation PressureWire is a proprietary hydrophilic coating that reduces friction within guide catheters and stent delivery catheters, allowing for easier deployment of stents and coronary balloons.
“In the evolution of our PressureWire family, we have long sought to
match or exceed the handling performance of conventional workhorse PCI
guidewires, a significant challenge owing to the presence of the
pressure sensor and signal cables,” said
When integrated into routine lab procedures, measuring FFR, as shown by
the FAME (Fractional Flow Reserve versus Angiography for Multivessel
Evaluation) study, sponsored by
About Fractional Flow Reserve (FFR)
Fractional Flow Reserve (FFR) is an index determining the functional severity of narrowings in the coronary arteries, and it is measured by PressureWire Aeris or PressureWire Certus. FFR specifically identifies which coronary narrowings are responsible for significantly obstructing the flow of blood to a patients’ heart muscle (called ischemia), and it is used by the interventional cardiologist to direct coronary interventions and assess results for improved treatment outcomes.
This news release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. Such forward-looking statements include the
expectations, plans and prospects for the Company, including potential
clinical successes, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market shares.
The statements made by the Company are based upon management’s current
expectations and are subject to certain risks and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control and the
risk factors and other cautionary statements described in the Company’s
filings with the